Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Inhibikase Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −3 vs. Q1 2023
- Shares held
- 747.1K
- +10.3K (+1.4%) vs. Q1 2023Converted for a 1-for-6 split
- Total value
- $2.69M
- −$213.4K (−7.3%) vs. Q1 2023
- New holders
- 3
- 4 more added
- Sold out
- 6
- 1 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 496,547 | $1.79M | 0.05% | +3,054+0.6% | AddedConverted for a 1-for-6 split |
| Vanguard Group Inc | 88,310 | $318.8K | 0.00% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Blair William & Co | 57,888 | $209.0K | 0.00% | +11,888+25.8% | AddedConverted for a 1-for-6 split |
| Redmond Asset Management, LLC | 20,976 | $75.7K | 0.02% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Edgewood Management LLC | 16,667 | $60.2K | 0.00% | +16,667 | New |
| Geode Capital Management, LLC | 14,840 | $51.6K | 0.00% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Hamilton Lane Advisors LLC | 13,802 | $49.8K | 0.02% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Renaissance Technologies LLC | 12,722 | $46.0K | 0.00% | +1,505+13.4% | AddedConverted for a 1-for-6 split |
| Barclays PLC | 11,455 | $41.4K | 0.00% | +11,455 | New |
| State Street Corp | 10,082 | $35.1K | 0.00% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Tower Research Capital LLC (TRC) | 1,984 | $7.16K | 0.00% | −238−10.7% | ReducedConverted for a 1-for-6 split |
| Morgan Stanley | 1,667 | $6.02K | 0.00% | 00.0% | UnchangedConverted for a 1-for-6 split |
| Wells Fargo & Company | 196 | $707 | 0.00% | +4+2.0% | AddedConverted for a 1-for-6 split |
| JPMorgan Chase & Co | 2 | $7 | 0.00% | +2 | New |
| Koshinski Asset Management, Inc. | 0 | $0 | 0.00% | −9,613−100.0% | Sold outConverted for a 1-for-6 split |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −6,501−100.0% | Sold outConverted for a 1-for-6 split |
| Retirement Planning Co of New England, Inc. | 0 | $0 | 0.00% | −5,817−100.0% | Sold outConverted for a 1-for-6 split |
| CCG Wealth Management, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold outConverted for a 1-for-6 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −4,812−100.0% | Sold outConverted for a 1-for-6 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −2,245−100.0% | Sold outConverted for a 1-for-6 split |